Otonomy (OTIC): Otipro Setting Up For Sales Inflection - Piper Jaffray

August 16, 2016 8:15 AM EDT
Get Alerts OTIC Hot Sheet
Price: $16.55 -1.78%

Rating Summary:
    6 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 1 | New: 2
Trade OTIC Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating on shares of Otonomy (NASDAQ: OTIC) now that the launch of OTIC's Otiprio for children undergoing bilateral tympanostomy tube placement (TTP) is underway. Commentary on the company's 2Q earnings call suggests strong progress working with payors and hospital P&T committees to enable access. The analyst expects these efforts to continue throughout the year and to position the company for a sales inflection point around the time of the winter season. There are a number of key data readouts over the next 12-18 months that may meaningfully expand the outlook for the OTIC's franchise. With a modest $240M enterprise value and roughly an equivalent cash position, Otiprio for TTP alone should be able to drive upside over the longer term, and assuming success with any new indication, potential additional and substantive upside awaits.

No change to the price target of $32 which reflects roughly 100% upside.

For an analyst ratings summary and ratings history on Otonomy click here. For more ratings news on Otonomy click here.

Shares of Otonomy closed at $17.02 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray, Earnings, Joshua Schimmer

Add Your Comment